Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.61 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | TNKS | O95271 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046069 | 0.90 | AR (0.65) | ARPGR | |
| SCHEMBL20046577 | 0.90 | AR (0.64) | ARPGRTNKSPARP1PARP2 | |
| SCHEMBL22557880 | 0.89 | AR (0.66) | ARPGRTNKSPARP1PARP2 | |
| SCHEMBL22557879 | 0.89 | AR (0.66) | ARPGRTNKSPARP1PARP2 | |
| SCHEMBL22557805 | 0.88 | AR (0.64) | ARPGRTNKSPARP1PARP2 | |
| SCHEMBL22557804 | 0.88 | AR (0.64) | ARPGRTNKSPARP1PARP2 | |
| SCHEMBL30349579 | 0.88 | AR (0.64) | ARPGRTNKSPARP1PARP2 | |
| SCHEMBL22047541 | 0.87 | AR (0.61) | ARPGRTNKSPARP1PARP2 | |
| SCHEMBL24031421 | 0.87 | AR (0.71) | ARPGRTNKSPARP1PARP2 | |
| SCHEMBL22006069 | 0.87 | AR (0.71) | ARPGRTNKSPARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | ANHORN MEDICINES CO., LTD. (TW) | 2024-01-18 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | AR 1/4885PGR 311/4885TNKS 2586/4885 |
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | MDM2, PSMG3, ADRM1 | AR 2577/4885PGR 3489/4885TNKS 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.